Pfizer taps Chinese expertise for novel drugs for MDR-TB
This article was originally published in Scrip
Pfizer has entered into an agreement for collaborative research with MicuRx Pharmaceuticals and MicuRx's Chinese affiliate, Cumencor Pharmaceuticals, for the development of novel therapeutics against multi-drug-resistant tuberculosis (MDR-TB).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.